We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Shares of Glaukos Corporation (GKOS - Free Report) have declined 17.1% as of Aug 11, 2020, despite delivering better-than-expected results.
The company reported second-quarter 2020 loss per share of 61 cents, narrower than the Zacks Consensus Estimate of a loss of 78 cents. Notably, the company had delivered earnings per share (EPS) of 1 cent in the prior-year quarter.
Revenues in Detail
Quarterly net sales totaled $31.6 million, which surpassed the Zacks Consensus Estimate by 55.9%. On a year-over-year basis, however, revenues plunged 46.1%. Per management, the downside can be attributed disruptions related to the COVID-19 pandemic. However, contribution from the Avedro buyout partially mitigated the downside.
Quarter Details
Gross profit in the second quarter was $9.9 million, down 80.5% year over year. Gross margin was 31.3% of net revenues, down 5530 basis points on a year-over-year basis.
Glaukos Corporation Price, Consensus and EPS Surprise
Operating expenses increased 0.2% to $57.1 million on a year-over-year basis, courtesy of higher selling, general and administrative, and research and development expenses.
Operating loss in the quarter under review was $47.2 million, substantially wider than the year-ago quarter’s loss of $6.2 million.
Financial Update
The company exited the second quarter with cash and cash equivalents of $266.9 million, down from $53.6 million on a sequential basis.
During the second quarter, total current assets came in at $453.2 million compared with $231.4 million in the preceding quarter.
2020 Guidance
Glaukos has withdrawn its previously announced (Feb 27, 2020) annual guidance for 2020 due to the rapidly evolving environment and continued uncertainties stemming from the COVID-19 pandemic. At this point, the company is unable to estimate the scope and duration of the impact of the pandemic on its financial and operating results.
Our Take
Glaukos exited the second quarter on a strong note. However, the company witnessed a weak quarter, reflecting decline in revenues at its global Glaucoma franchise. The company also reported a fall in revenues in the second quarter. It also faces cut-throat competition in the Medical Devices space. The company witnessed a contraction in its gross margin in the quarter under review.
Nonetheless, advancement in its market-expanding pipeline and execution of quite a few business development growth initiatives that include the Avedro buyout buoys optimism.
Zacks Rank
Glaukos carries a Zacks Rank #3 (Hold).
Key Picks
Some better-ranked stocks in the broader medical space are Thermo Fisher Scientific Inc. (TMO - Free Report) , PerkinElmer, Inc. and West Pharmaceutical Services, Inc. (WST - Free Report) . While PerkinElmer sports a Zacks Rank of 1 (Strong Buy), both Thermo Fisher and West Pharmaceuticals carry a Zacks Rank #2 (Buy). You can seethe complete list of today’s Zacks #1 Rank stocks here.
PerkinElmer reported second-quarter 2020 adjusted EPS of $1.57, surpassing the Zacks Consensus Estimate by 68.8%. Revenues of $811.7 million outpaced the consensus mark by 1.3%.
Thermo Fisher reported second-quarter 2020 adjusted EPS of $3.89, beating the Zacks Consensus Estimate by 45.7%. Revenues of $6.92 billion surpassed the consensus mark by 0.1%.
West Pharmaceuticals reported second-quarter 2020 adjusted EPS of $1.25, outpacing the Zacks Consensus Estimate of 91 cents. Revenues of $527.2 million surpassed the consensus estimate by 6.9%.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
Glaukos (GKOS) Loses 17.1% Despite Q2 Earnings & Revenues Beat
Shares of Glaukos Corporation (GKOS - Free Report) have declined 17.1% as of Aug 11, 2020, despite delivering better-than-expected results.
The company reported second-quarter 2020 loss per share of 61 cents, narrower than the Zacks Consensus Estimate of a loss of 78 cents. Notably, the company had delivered earnings per share (EPS) of 1 cent in the prior-year quarter.
Revenues in Detail
Quarterly net sales totaled $31.6 million, which surpassed the Zacks Consensus Estimate by 55.9%. On a year-over-year basis, however, revenues plunged 46.1%. Per management, the downside can be attributed disruptions related to the COVID-19 pandemic. However, contribution from the Avedro buyout partially mitigated the downside.
Quarter Details
Gross profit in the second quarter was $9.9 million, down 80.5% year over year. Gross margin was 31.3% of net revenues, down 5530 basis points on a year-over-year basis.
Glaukos Corporation Price, Consensus and EPS Surprise
Glaukos Corporation price-consensus-eps-surprise-chart | Glaukos Corporation Quote
Operating expenses increased 0.2% to $57.1 million on a year-over-year basis, courtesy of higher selling, general and administrative, and research and development expenses.
Operating loss in the quarter under review was $47.2 million, substantially wider than the year-ago quarter’s loss of $6.2 million.
Financial Update
The company exited the second quarter with cash and cash equivalents of $266.9 million, down from $53.6 million on a sequential basis.
During the second quarter, total current assets came in at $453.2 million compared with $231.4 million in the preceding quarter.
2020 Guidance
Glaukos has withdrawn its previously announced (Feb 27, 2020) annual guidance for 2020 due to the rapidly evolving environment and continued uncertainties stemming from the COVID-19 pandemic. At this point, the company is unable to estimate the scope and duration of the impact of the pandemic on its financial and operating results.
Our Take
Glaukos exited the second quarter on a strong note. However, the company witnessed a weak quarter, reflecting decline in revenues at its global Glaucoma franchise. The company also reported a fall in revenues in the second quarter. It also faces cut-throat competition in the Medical Devices space. The company witnessed a contraction in its gross margin in the quarter under review.
Nonetheless, advancement in its market-expanding pipeline and execution of quite a few business development growth initiatives that include the Avedro buyout buoys optimism.
Zacks Rank
Glaukos carries a Zacks Rank #3 (Hold).
Key Picks
Some better-ranked stocks in the broader medical space are Thermo Fisher Scientific Inc. (TMO - Free Report) , PerkinElmer, Inc. and West Pharmaceutical Services, Inc. (WST - Free Report) . While PerkinElmer sports a Zacks Rank of 1 (Strong Buy), both Thermo Fisher and West Pharmaceuticals carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
PerkinElmer reported second-quarter 2020 adjusted EPS of $1.57, surpassing the Zacks Consensus Estimate by 68.8%. Revenues of $811.7 million outpaced the consensus mark by 1.3%.
Thermo Fisher reported second-quarter 2020 adjusted EPS of $3.89, beating the Zacks Consensus Estimate by 45.7%. Revenues of $6.92 billion surpassed the consensus mark by 0.1%.
West Pharmaceuticals reported second-quarter 2020 adjusted EPS of $1.25, outpacing the Zacks Consensus Estimate of 91 cents. Revenues of $527.2 million surpassed the consensus estimate by 6.9%.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2020 today >>